No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment.

D Plachouras, E Giannitsioti, S Athanassia, F Kontopidou, A Papadopoulos, K Kanellakopoulou, H Giamarellou

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(9):e89-91

PMID: 17029128

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.

Address: Fourth Department of Internal Medicine, Attiko University General Hospital, Haidari, Greece. [email protected]

DOI: 10.1086/508280

Link outs

Free resources

Medical:

https://medlineplus.gov/anemia.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Acetamides, Anemia, Anti-Bacterial Agents, Female, Humans, Incidence, Linezolid, Male, Middle Aged, Oxazolidinones, Pyridoxine, Thrombocytopenia